A Janikova
Overview
Explore the profile of A Janikova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hricko S, Navrkalova V, Navrkalova V, Janikova A
Klin Onkol
. 2024 Jan;
36(4):273-280.
PMID: 38195381
Background: Malignant lymphomas represent a highly heterogeneous group of tumors with varied clinical behavior - from indolent to very aggressive forms with survival in the order of months. From the...
2.
Janikova A, Michalka J, Chloupkova R, Kopalova N, Campr V, Kamaradova K, et al.
Ann Hematol
. 2022 Jan;
101(4):789-798.
PMID: 35061088
Mature T cell lymphomas (MTCLs) have worse prognosis, and in contrast to B cell lymphomas, there is no universal marker like CD20 with exception of ALK and CD30, which are...
3.
Gonzalez-Barca E, Boumendil A, Blaise D, Trneny M, Masszi T, Finel H, et al.
Bone Marrow Transplant
. 2019 Sep;
55(2):393-399.
PMID: 31541205
Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-term outcome of those who...
4.
can V, Moravcik P, Janikova A, Kala Z, Panek J, Penka I
Rozhl Chir
. 2019 Aug;
98(8):328-334.
PMID: 31462056
Surgical treatment of gastrointestinal solid tumors is the basic method with a curative potential. However, the first-line treatment modalities in lymphomas are systemic oncology therapy (chemotherapy, immunotherapy and hematopoietic stem...
5.
Devan J, Musilova K, Janikova A, Mraz M
Klin Onkol
. 2017 Aug;
30(4):247-257.
PMID: 28832170
The molecular pathogenesis of follicular lymphoma (FL) was partially revealed by the discovery of BCL2 translocations to the region encoding the immunoglobulin heavy chain, which accompany the vast majority of...
6.
Musilova K, Devan J, Zlamalikova L, Kren L, Mocikova H, Prochazka V, et al.
Klin Onkol
. 2017 May;
30(Supplementum1):163-165.
PMID: 28471196
Background: Molecular pathogenesis of follicular lymphoma (FL) is characterized by substantial dysregulation of epigenetic regulators. Many cases of FL are associated with the aberrant expression of non-coding regulatory RNAs, namely...
7.
Sykorova A, Pytlik R, Mocikova H, Belada D, Benesova K, Papajik T, et al.
Klin Onkol
. 2016 Aug;
29(4):295-302.
PMID: 27534788
Background: Recent advances in the use of the imaging modalities, especially PET/CT, and their utilization for determining clinical stage (CS) and assessment treatment response (TR) in malignant lymphomas, along with...
8.
Krejci M, Janikova A, Folber F, Kral Z, Mayer J
Neoplasma
. 2015 Aug;
62(5):787-92.
PMID: 26278142
Mobilization of peripheral blood stem cells (PBSC) using the granulocyte colony-stimulating factor (G-CSF) has enabled the collection even from older donors and those with comorbidities. Several clinical parameters have been...
9.
Tomiska M, Novotna S, Klvacova L, Tumova J, Janikova A
Klin Onkol
. 2015 Apr;
28(2):99-104.
PMID: 25882019
Recent knowledge on vitamin D has shown that its active form not only regulates calcium and phosphate metabolism but also has significant antimitotic and cell differentiation effects. It can inhibit...
10.
Dedeckova K, Mocikova H, Belada D, Janikova A, Doleckova M, Malinova B, et al.
Klin Onkol
. 2013 May;
26(2):99-109.
PMID: 23718668
Background: Indication of radiotherapy in lymphoma treatment is an important strategic decision requiring comprehensive expertise. It also calls for a better definition of the position of radiotherapy in clinical practice....